Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness
Volume: 29, Issue: 7, Pages: 786 - 795
Published: Dec 11, 2019
Abstract
Purpose To describe utilization of filgrastim and infliximab, the first two products with biosimilars approved in the United States. Methods We identified use of filgrastim (reference, tbo‐filgrastim, and filgrastim‐sndz) and infliximab (reference, infliximab‐dyyb, and infliximab‐abda) in the Sentinel Distributed Database using Healthcare Common Procedure Coding System (HCPCS) codes and National Drug Codes (NDCs) from January 2015 to August...
Paper Details
Title
Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness
Published Date
Dec 11, 2019
Volume
29
Issue
7
Pages
786 - 795
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History